Ribociclib Succinate

Preferred Label : Ribociclib Succinate;

NCIt definition : The succinate salt form of ribociclib, an orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity. Upon oral administration, ribociclib specifically targets, binds to and inhibits CDK4 and CDK6. This inhibits the cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, which inhibits phosphorylation of the retinoblastoma (Rb) protein. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle dysregulation.;

UNII : BG7HLX2919;

InChIKey : NHANOMFABJQAAH-UHFFFAOYSA-N;

CAS number : 1374639-75-4;

Drug name : Kisqali;

NCI Metathesaurus CUI : CL553414;

Details

Origin ID

C152210;

UMLS CUI

C4318037;

Currated CISMeF NLP mapping
- Ribociclib succinate [SMS substance]
- Ribociclib succinate (substance) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Ribociclib succinate (substance) [SNOMED CT concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_free_acid_or_base_form
- Ribociclib [NCIt concept]
is_salt_form_of
- Ribociclib [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients